Education
🎓 Prof. Maurer completed his medical training and residency at the Technical University of Munich (TUM) from 1997 to 2009. His dedication to academic excellence laid the foundation for a distinguished career in urology and prostate cancer research.
Experience
🏥 Prof. Maurer has held prominent positions throughout his career. He served as a Urologist and Attending Urologist at TUM’s Department of Urology from 2009 to 2016, followed by his role as Senior Attending Urologist in 2017-2018. Since 2018, he has been a vital part of the Martini-Klinik, contributing significantly to patient care and clinical research.
Awards and Honors
🏆 Prof. Maurer has received over 30 national and international accolades, highlighting his contributions to uro-oncology. Key awards include the 2017 German Urological Association (DGU) Award for Research and Innovation in Uro-Oncology, the 2015 EAU-AUA Scientific Exchange Programme Stipend (USA), and a Stipend from the German Research Foundation (2000–2002).
Research Focus
🔬 Dr. Maurer’s research centers on prostate cancer imaging, surgery, and therapy, particularly PSMA-PET imaging and radioguided surgery. He has served as co-investigator in over 30 clinical studies and as principal investigator for four clinical trials. With an h-index of 50 and more than 220 publications (impact factor >900), his contributions to urological science are substantial.
Conclusion
🌟 Prof. Dr. Tobias Maurer’s expertise and dedication to advancing prostate cancer care have established him as a leader in the field of urology. His clinical innovations, academic achievements, and numerous accolades reflect his commitment to improving patient outcomes globally.
Publications
Assessment of Different Castration Resistance Definitions and Staging Modalities in Metastatic Castration-Resistant Prostate Cancer
🗓️ Cancers, 2024-10-17
DOI: 10.3390/cancers16203506
Comparative analysis of robot-assisted and open approach for PSMA-radioguided surgery in recurrent prostate cancer
🗓️ European Journal of Nuclear Medicine and Molecular Imaging, 2024-08
DOI: 10.1007/s00259-023-06460-5
Nerve-sparing radical prostatectomy using the neurovascular structure-adjacent frozen-section examination (NeuroSAFE): results after 20 years of experience
🗓️ Prostate Cancer and Prostatic Diseases, 2024-06-11
DOI: 10.1038/s41391-024-00851-x
Limited prognostic role of routine serum markers (AP, CEA, LDH, and NSE) in oligorecurrent prostate cancer patients undergoing PSMA-radioguided surgery
🗓️ World Journal of Urology, 2024-04-24
DOI: 10.1007/s00345-024-04948-9
PSA-density, DRE, and PI-RADS 5: potential surrogates for omitting biopsy?
🗓️ World Journal of Urology, 2024-03-20
DOI: 10.1007/s00345-024-04894-6
PSMA-targeted fluorescence guidance for robotic-assisted prostatectomy
🗓️ Nature Reviews Urology, 2023-12
DOI: 10.1038/s41585-023-00817-z
EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer
🗓️ Cancers, 2023-10
DOI: 10.3390/cancers15205008